Skip to main content
JWCTF logo

JW (Cayman) Therapeutics Co. Ltd (JWCTF) Stock Price & Analysis

JW (Cayman) Therapeutics Co. Ltd (JWCTF) — price $0.2022 (0.00%), as of the Nov 19, 2026 trading session; market cap $84.3M.

Educational signal · not a buy or sell recommendation · How to read this

$0.2022 $0.00 (0.00%) Market Cap $84.3M

JW (Cayman) Therapeutics Co. Ltd · JWCTF

JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology firm focused on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company's pipeline includes its lead CAR-T product, Carteyva, alongside other innovative T-cell therapies targeting various oncology indications.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.2022
Change on the day0.00%
Market capitalisation$84.3M
Shares traded on the day55.5K

Price & events

Other perspectives

Council score for JW (Cayman) Therapeutics Co. (JWCTF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Oct 2, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Neutral
ROE Negative
Gross Margin Moderate

Read on: Oct 2, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Oct 2, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is JW (Cayman) Therapeutics Co. (JWCTF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. JW (Cayman) Therapeutics Co. Ltd (JWCTF) is the company analyzed here. It employs 303 people. In Q2 FY2026 it reported revenue of CN¥111M and net income of -CN¥50M. The market values it at $84.3M.

2 · Latest results

What do the latest results show for JW (Cayman) Therapeutics Co. (JWCTF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CN¥111M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CN¥111M-CN¥50M-CN¥0.12 (diluted)
Q4 FY2025CN¥174M-CN¥283M-CN¥0.68 (diluted)
Q2 FY2025CN¥106M-CN¥267M-CN¥0.64 (diluted)
Q4 FY2024CN¥71M-CN¥350M-CN¥0.84 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for JW (Cayman) Therapeutics Co. (JWCTF)?

Short answer · as of

The distress and quality screens read Altman Z -10.00 · Piotroski F 2. Trailing ratios: ROE -66.2% · ROA -40.1% · current ratio 1.43 · earnings yield -37.6% · free-cash-flow yield -12.6%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -10.00 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-66.2%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held JWCTF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported JWCTF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: JWCTF Stock

These answers are editorial: 1 of these 8 answers is drawn from the JWCTF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is JWCTF a good stock to buy?

Stock Expert AI does not rate JWCTF buy, sell or hold. JW (Cayman) Therapeutics Co. Ltd has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the JWCTF stock price today?

The last price recorded for JW (Cayman) Therapeutics Co. Ltd (JWCTF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for JWCTF?

The primary risks for JWCTF stem from its nature as a clinical-stage biotechnology company and its OTC market listing. Significant risks include potential clinical trial failures or unexpected safety issues, which could halt product development and lead to substantial financial losses.

What are the key factors to evaluate for JWCTF?

Evaluate JWCTF on fundamentals, analyst consensus, and risk factors. Not financial advice.

How frequently does JWCTF data refresh on this page?

JWCTF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven JWCTF's recent stock price performance?

JW (Cayman) Therapeutics Co. Ltd (JWCTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced clinical-stage pipeline with lead CAR-T product Carteyva for hematological cancers. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider JWCTF overvalued or undervalued right now?

JW (Cayman) Therapeutics Co. Ltd (JWCTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research JWCTF before investing?

Before investing in JW (Cayman) Therapeutics Co. Ltd (JWCTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 9 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.